Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).

Published

Conference Paper

Full Text

Published version (via Digital Object Identifier)

Duke Authors

Cited Authors

Sampson, JH; Vlahovic, G; Desjardins, A; Friedman, HS; Baehring, JM; Hafler, D; Rollin, L; Coric, V; Perez, SN; Reardon, DA

Published Date

May 20, 2014

Published In

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Volume / Issue

32 / 15_suppl

Start / End Page

TPS2101 - TPS2101

Published By

American Society of Clinical Oncology (ASCO)

Electronic International Standard Serial Number (EISSN)

1527-7755

International Standard Serial Number (ISSN)

0732-183X

Digital Object Identifier (DOI)

10.1200/jco.2014.32.15_suppl.tps2101